Allergy Clinical Trial - Clinical Investigation on Allergic-like Reactions

Status Active, not recruiting

Clinical Trial Summary

During the 2009-2010 immunization campaign against pandemic H1N1, some people reported having allergic-like reactions (anaphylaxis(a shock-like reaction), hives, swelling, etc.). A vaccine allergy may be more or less severe or intense. Patients may have skin reactions (rash with or without itching), respiratory problems (cough, spasm of the airways), angioedema (swelling) of various body parts (face, eyelids, throat etc.) and circulatory problems (low blood pressure or shock). Anaphylaxis is a severe allergic reaction that can sometimes be fatal. Other people vaccinated against pandemic H1N1 had an oculo-respiratory syndrome. Oculo-respiratory syndrome (ORS) is also a reaction to the influenza vaccine, which includes symptoms such as bilateral conjunctivitis (red eyes) with swelling of the face or respiratory symptoms (chest tightness, coughing, a sensation of throat closure, difficulty swallowing, hoarseness, wheezing or difficulty breathing). The investigators know that ORS is not a true allergic reaction. Because many signs and symptoms of ORS are similar to those observed during an allergic reaction, it is often difficult to distinguish ORS from an allergic reaction.

This study will compare three groups of patients: those who had allergic-like reactions, those who had ORS and vaccinated individuals who had no such adverse events. Pregnant women cannot participate in this study. The study has three goals. First, the investigators want to determine, among those who had allergic-like reactions after influenza vaccination, what proportion (percentage) of these people are actually allergic to the vaccine or its components. Second, among those who are not allergic to the vaccine, which other processes may have caused these symptoms. Finally, the investigators will try to identify whether there are features that distinguish patients who have a true allergic reaction from those affected by ORS, and those that had no adverse events.

Clinical Trial Description

n/a

Study Design

Observational Model: Case Control, Time Perspective: Retrospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01247415
Study type	Observational
Source	PHAC/CIHR Influenza Research Network
Contact
Status	Active, not recruiting
Phase	N/A
Start date	January 2011
Completion date	November 2012

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02032056` - Effect of Probiotics in Reducing Infections and Allergies in Young Children During the Complementary Feeding Period	N/A
Completed	`NCT01842711` - Cumulative Irritation Patch Test	N/A
Completed	`NCT01633840` - New Validated Recipes for Double-blind Placebo-controlled Low Dose Food Challenges	N/A
Completed	`NCT00554983` - Efficacy and Safety From a Recombinant Folding Variant of Bet v 1	Phase 3
Completed	`NCT00997971` - Growth, Tolerance in Healthy Infants Fed a Partially Hydrolyzed Rice Protein	Phase 3
Completed	`NCT00331929` - Respiratory Health Study of Children in Kiryat Tivon	N/A
Completed	`NCT00232518` - Randomised Controlled Clinical Trials of the Effect of Therapeutic Hookworm Infection in Allergic Rhinoconjunctivitis	N/A
Completed	`NCT00220753` - Air Cleaners for Children and Adolescents With Asthma and Dog Allergy	N/A
Completed	`NCT04126096` - Negative Predictive Value and NIC of Beta-Lactam Antibiotics.	N/A
Completed	`NCT04046731` - Neuromuscular Blocking Agents Utilized During Perioperative Hypersensitivity Evaluation	N/A
Completed	`NCT04004351` - Treatment Modalities in Children and Adolescents Suffering From HDM-induced Allergic Rhinitis and/or Asthma
Not yet recruiting	`NCT05997784` - Study of Indoor Air Pollutants and Their Impact in Childhood Health and Wellbeing
Completed	`NCT04418999` - Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus	Early Phase 1
Completed	`NCT04186949` - Early Origins of Allergy and Asthma
Completed	`NCT02127801` - Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants	Phase 1
Enrolling by invitation	`NCT05011071` - The Alberta BLOOM Premature Child Study
Not yet recruiting	`NCT06330974` - Allergy, Asthma, and Atopic Eczema in Finland
Completed	`NCT02306473` - The Leaky Lung Test	Early Phase 1
Terminated	`NCT02601690` - Observational Analysis of T Cell Responses to SPIREs for Multiple Allergens in Subjects With Allergy in North America
Completed	`NCT02596321` - A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and/or Atopic Asthma	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Investigation on Allergic-like Reactions and Oculo-respiratory Syndrome After the H1N1 Pandemic Vaccine

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms